Suppr超能文献

酮康唑的制剂、表征及其扩大生产:提高溶出度和生物利用度

Preparation, characterization, and scale-up of ketoconazole with enhanced dissolution and bioavailability.

作者信息

Elder Edmund J, Evans Jonathan C, Scherzer Brian D, Hitt James E, Kupperblatt Gary B, Saghir Shakil A, Markham Dan A

机构信息

Dowpharma, The Dow Chemical Company, Midland, Michigan, USA.

出版信息

Drug Dev Ind Pharm. 2007 Jul;33(7):755-65. doi: 10.1080/03639040601031882.

Abstract

Many new molecular entities targeted for pharmaceutical applications face serious development challenges because of poor water solubility. Although particle engineering technologies such as controlled precipitation have been shown to enhance aqueous dissolution and bioavailability of poorly water soluble active pharmaceutical ingredients, the data available are the results of laboratory-scale experiments. These technologies must be evaluated at larger scale to ensure that the property enhancement is scalable and that the modified drugs can be processed on conventional equipment. In experiments using ketoconazole as the model drug, the controlled precipitation process was shown to produce kg-scale modified drug powder with enhanced dissolution comparable to that of lab-scale powder. Ketoconazole was demonstrated to be stable throughout the controlled precipitation process, with a residual methanol level below the ICH limit. The modified crystalline powder can be formulated, and then compressed using conventional high-speed tableting equipment, and the resulting tablets showed bioavailability more than double that of commercial tablets. When appropriately protected from moisture, both the modified powder and tablets prepared from the modified powder showed no change in dissolution performance for at least 6 months following storage at accelerated conditions and for at least 18 months following storage at room temperature.

摘要

许多针对制药应用的新分子实体由于水溶性差而面临严峻的开发挑战。尽管诸如控制沉淀等颗粒工程技术已被证明可提高难溶性活性药物成分的水溶解率和生物利用度,但现有的数据都是实验室规模实验的结果。这些技术必须在更大规模上进行评估,以确保性能增强是可扩展的,并且改性药物可以在传统设备上进行加工。在以酮康唑为模型药物的实验中,控制沉淀过程被证明可生产出千克级的改性药物粉末,其溶解率提高,与实验室规模的粉末相当。酮康唑在整个控制沉淀过程中被证明是稳定的,残留甲醇水平低于国际协调会议(ICH)的限值。改性结晶粉末可以进行配方,然后使用传统的高速压片设备进行压制,所得片剂的生物利用度比市售片剂高出一倍多。当适当防潮时,改性粉末以及由改性粉末制备的片剂在加速条件下储存至少6个月以及在室温下储存至少18个月后,其溶解性能均未发生变化。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验